ArticleFrontiers in pediatrics2026
Agreement and diagnostic performance of a smartphone-based bilirubin assessment tool for screening neonatal hyperbilirubinemia.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Accuracy of non-invasive smartphone bilirubin measurements on neonates before and during phototherapy.European journal of pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neonatal hyperbilirubinemia is common and may lead to severe neurological injury if not detected and treated promptly. Total serum bilirubin (TSB) remains the reference standard, while transcutaneous bilirubin (TcB) is commonly used for non-invasive screening. Smartphone-based bilirubin assessment may provide a supplementary approach for neonatal jaundice screening. Objective: This study aimed to evaluate the agreement, correlation, and diagnostic performance of a self-developed mobile application for bilirubin measurement compared with TSB and TcB in screening neonatal hyperbilirubinemia. Methods: This prospective diagnostic study was conducted in the neonatal department of Anhui Provincial Hospital, China, between March 2025 and January 2026. Eligible neonates undergoing clinically indicated TSB testing for jaundice before phototherapy were included. TSB, TcB, and mobile app-derived bilirubin measurements were obtained during the same assessment session. Using TSB as the reference standard, agreement between mobile app-derived bilirubin and TSB was assessed using Bland-Altman analysis, and correlation was evaluated using linear regression. Multivariable logistic regression models adjusted for gestational age, postnatal age, and birth weight were used to evaluate diagnostic performance, and receiver operating characteristic curves were generated from predicted probabilities. Results: Among 121 neonates, 46 were preterm and 75 were term infants. In the overall cohort, mobile app-derived bilirubin did not differ significantly from TSB, with a mean difference of -2.42 μmol/L and 95% limits of agreement from -30.57 to 25.73 μmol/L. Agreement was lower among preterm infants than among term infants. Mobile app-derived bilirubin was positively correlated with TSB ( Conclusion: Mobile application-derived bilirubin showed good agreement with TSB and diagnostic performance comparable to TcB under standardized conditions. Owing to its non-invasive, convenient, and low-cost nature, this smartphone-assisted approach has potential as a supplementary tool for neonatal hyperbilirubinemia screening, pending further technical optimization and multicenter home-based validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.